ArticleFrontiers in oncology2023

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

Viktor Grünwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.